DEA Moves to Place Kratom, Mitragynine, and 7-Hydroxymitragynine into Schedule I
The DEA has announced that they will be officially publishing a notice of intent to place the primary active constituents of Kratom into Schedule I, under the temporary scheduling provisions of the Controlled Substances Act:
Kratom is a fairly popular herbal remedy for athletes suffering from injuries or chronic pain, and has been on the DEA’s radar for at least the past decade (which I know based on a Freedom of Information request I filed with them). This makes it a bit odd that they would now be giving notice of temporary scheduling, based on their claim that Kratom is an imminent hazard to the public safety.
In fact, none of the documents or scientific data I’ve seen provided by the DEA or by the FDA pursuant to FOIA requests would even remotely indicate that Kratom is the kind of herb that fits into Schedule 1, the most severe category, reserved for drugs that have no medical use and a strong potential for abuse.
The supplement industry has been asking for answers from the FDA for years, regarding their thoughts on Kratom as a dietary supplement apparently to no avail.
And now this.